Zepatier in Patients with Substance Use

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

September 9, 2022

Conditions

Hepatitis CHivCoinfection, HIVSubstance Use Disorders

Interventions

DRUG

Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]

Daily medication

Trial Locations (1)

University of Illinois at Chicago, Chicago

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT04048850 - Zepatier in Patients with Substance Use | Biotech Hunter | Biotech Hunter